Remifentanil (Ultiva™), a fentanyl derivative, is an ultra-short acting, nonspecific esterase-
metabolised, selective μ-opioid receptor agonist, with a pharmacodynamic profile typical of …

The anilidopiperidine opioid remifentanil has pharmacodynamic properties similar to all
opioids; however, its pharmacokinetic characteristics are unique. Favourable …

Remifentanil has been approved for clinical use in the United States since July 1996. This
new opioid is now in regular clinical use in many countries worldwide. This progress is …

Importance of the field: Opioids play an important role in every aspect of modern anesthetic
practice. Remifentanil is an ultra-short-acting opioid featuring a unique pharmacokinetic …

Remifentanil hydrochloride is a potent opioid analgesic with unique pharmacokinetic
properties, including rapid onset of action and short duration of effect. These characteristics …

Most opioids used in anaesthesia are of the anilidopiperidine family, including fentanyl,
alfentanil, sufentanil and remifentanil. While all share similar pharmacological properties …

Remifentanil is the newest of the fentanyl family of short-acting phenylpiperidine derivatives
to be released into clinical practice. Remifentanil is a pure agonist at the μ opioid receptor …

Remifentanil is a fentanyl derivative with an ester linkage(3-[4-methoxycarbonyl-4-[(1-
oxopropyl) phenylamino]-1-piperidine] propanoic acid, methyl ester). It is a pure aµ agonist …

Opioids decrease the sympathetic and somatic responses to noxious stimulation and can be
given in high doses without negative inotropic effects, even in patients with impaired cardiac …

Remifentanil is still in its infancy in terms of postmarketing development. Its appropriate role
in modern anesthesia care is still being defined and reports of novel clinical applications for …